Incyte and Syndax Announce FDA Approval of Niktimvo\u2122 (Axatilimab) in 9 mg and 22 mg Vials
Incyte and Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The companies expect the product to…
WHO Launches $1.5B Health Emergency Appeal
Unprecedented challenges such as conflict, climate change, epidemics, and displacement are converging to create a severe global health crisis, leaving 305 million people in dire need of humanitarian assistance in…
Orion Nomination Committee’s 2025 AGM Proposals
The Nomination Committee of Orion Corporation has provided its recommendations to the company’s Board of Directors regarding proposals for the 2025 Annual General Meeting (AGM). These recommendations address both the…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial…
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses At the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG revealed significant advancements in its pharmaceutical growth strategy, announcing multiple…
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease AskBio Inc., a leading gene therapy company and a subsidiary of Bayer AG, announced today that the…
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical…
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination…
Datopotamab Deruxtecan Receives Priority Review for Advanced EGFR+ NSCLC
Datopotamab Deruxtecan Granted Priority Review by FDA for Advanced EGFR-Mutated NSCLC AstraZeneca and Daiichi Sankyo recently announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License…
AbbVie & Simcere Partner on Trispecific Antibody for Multiple Myeloma
AbbVie and Simcere Zaiming Announce Partnership to Develop Novel Trispecific Antibody for Multiple Myeloma AbbVie a global leader in oncology and hematology, has joined forces with Simcere Zaiming, a subsidiary…
Lilly Updates 2024 Revenue Forecast and Announces 2025 Guidance
Eli Lilly and Company has announced its preliminary revenue guidance for 2024 and 2025, showcasing significant growth and momentum in its operations. For 2024, Lilly anticipates full-year worldwide revenue to…
Lilly to Acquire Scorpion Therapeutics Precision PI3Kα Inhibitor Program
Eli Lilly and Company and Scorpion Therapeutics a private biotechnology company specializing in small molecule precision oncology therapies, have announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor…